Geron slides on trial discontinuation

Geron Corp. (NASDAQ:GERN) fell $1.62 (56%) to $1.28 on Monday after discontinuing a Phase II trial of imetelstat to treat locally recurrent or metastatic breast cancer following interim data

Read the full 297 word article

User Sign In